

# Yee Chao

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/276646/publications.pdf>

Version: 2024-02-01

178  
papers

6,745  
citations

147566

31  
h-index

76769

74  
g-index

180  
all docs

180  
docs citations

180  
times ranked

8378  
citing authors

#	ARTICLE	IF	CITATIONS
1	Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study. <i>Gastric Cancer</i> , 2022, 25, 207-217.	2.7	9
2	Nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy: A real-world experience. <i>Journal of the Chinese Medical Association</i> , 2022, 85, 42-50.	0.6	6
3	Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study. <i>BMC Cancer</i> , 2022, 22, 55.	1.1	14
4	Microsatellite Instability, Epstein-Barr Virus, and Programmed Cell Death Ligand 1 as Predictive Markers for Immunotherapy in Gastric Cancer. <i>Cancers</i> , 2022, 14, 218.	1.7	13
5	AdvanTIG-206: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (BGB-A1217; OCI) plus anti-programmed cell death protein 1 (PD-1) mAb tislelizumab (TIS) plus BAT1706 versus (vs) TIS plus BAT1706 as first-line treatment for advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS488-TPS488.	0.8	0
6	Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2+ gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03.. <i>Journal of Clinical Oncology</i> , 2022, 40, 295-295.	0.8	17
7	Synergistic effect of Abraxane that combines human IL15 fused with an albumin-binding domain on murine models of pancreatic ductal adenocarcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 1955-1968.	1.6	4
8	Bifocal lesions have a poorer treatment outcome than a single lesion in adult patients with intracranial germinoma. <i>PLoS ONE</i> , 2022, 17, e0264641.	1.1	4
9	Differential prognoses among male and female patients with hepatocellular carcinoma. <i>Journal of the Chinese Medical Association</i> , 2022, 85, 554-565.	0.6	11
10	Correlation between drug sensitivity profiles of circulating tumour cell-derived organoids and clinical treatment response in patients with pancreatic ductal adenocarcinoma. <i>European Journal of Cancer</i> , 2022, 166, 208-218.	1.3	16
11	Compassionate Treatment of Brainstem Tumors with Boron Neutron Capture Therapy: A Case Series. <i>Life</i> , 2022, 12, 566.	1.1	3
12	Determinants of Survival and Post-Progression Outcomes by Sorafenib-Regorafenib Sequencing for Unresectable Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 2014.	1.7	5
13	Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience. <i>Investigational New Drugs</i> , 2022, 40, 789-797.	1.2	14
14	Comparison of prognoses between cirrhotic and noncirrhotic patients with hepatocellular carcinoma and esophageal varices undergoing surgical resection. <i>Journal of the Chinese Medical Association</i> , 2022, 85, 679-686.	0.6	5
15	Surgical resection could provide better outcomes for patients with hepatocellular carcinoma and tumor rupture. <i>Scientific Reports</i> , 2022, 12, 8343.	1.6	5
16	Durable objective response to sorafenib and role of sequential treatment in unresectable hepatocellular carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210994.	1.4	1
17	Outcomes of patients with malignant duodenal obstruction after receiving self-expandable metallic stents: A single center experience. <i>PLoS ONE</i> , 2022, 17, e0268920.	1.1	4
18	Role of organ-specific response to immune checkpoint inhibitor in survival for advanced hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, e16172-e16172.	0.8	0

#	ARTICLE	IF	CITATIONS
19	AdvanTIG-206: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (BGB-A1217; OCI) plus anti-programmed cell death protein-1 (PD-1) mAb tislelizumab (TIS) plus BAT1706 versus TIS plus BAT1706 as first-line (1L) treatment for advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2022, 40, TPS4172-TPS4172.	0.8	1
20	Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) and tislelizumab (TIS) as first-line (1L) therapy for patients (pts) with advanced HER2-positive gastric/gastroesophageal junction adenocarcinoma (G/GEJC): Preliminary results from a phase 1b/2 study.. Journal of Clinical Oncology, 2022, 40, 4032-4032.	0.8	6
21	Comparison of the Long-term Outcome Between Billroth-I and Roux-en-Y Reconstruction Following Distal Gastrectomy for Gastric Cancer. Journal of Gastrointestinal Surgery, 2021, 25, 1955-1961.	0.9	4
22	Prediction of survival according to kinetic changes of cytokines and hepatitis status following radioembolization with yttrium-90 microspheres. Journal of the Formosan Medical Association, 2021, 120, 1127-1136.	0.8	5
23	Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240. Cancer, 2021, 127, 865-874.	2.0	20
24	Effect of Primary Tumor Location on Postmetastasectomy Survival in Patients with Colorectal Cancer Liver Metastasis. Journal of Gastrointestinal Surgery, 2021, 25, 650-661.	0.9	9
25	Landmark analysis of overall survival (OS) by objective response (OR) in previously treated patients (pts) with advanced hepatocellular carcinoma (aHCC): Post-hoc analysis of the randomized, phase III KEYNOTE-240 study.. Journal of Clinical Oncology, 2021, 39, 318-318.	0.8	0
26	The role of albumin-bilirubin grade in determining the outcomes of patients with very early-stage hepatocellular carcinoma. Journal of the Chinese Medical Association, 2021, 84, 136-143.	0.6	8
27	Potential of circulating immune cells as biomarkers of nivolumab treatment efficacy for advanced hepatocellular carcinoma. Journal of the Chinese Medical Association, 2021, 84, 144-150.	0.6	8
28	Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab. Gastric Cancer, 2021, 24, 946-958.	2.7	61
29	Salvage Boron Neutron Capture Therapy for Malignant Brain Tumor Patients in Compliance with Emergency and Compassionate Use: Evaluation of 34 Cases in Taiwan. Biology, 2021, 10, 334.	1.3	33
30	Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial. Liver Cancer, 2021, 10, 275-284.	4.2	29
31	Significance of Kynurenine 3-Monooxygenase Expression in Colorectal Cancer. Frontiers in Oncology, 2021, 11, 620361.	1.3	12
32	Clinical and Immunologic Responses to a B-Cell Epitope Vaccine in Patients with HER2/neu-Overexpressing Advanced Gastric Cancer-Results from Phase Ib Trial IMU.ACS.001. Clinical Cancer Research, 2021, 27, 3649-3660.	3.2	23
33	Lenvatinib plus pembrolizumab versus lenvatinib in patients with unresectable hepatocellular carcinoma: A real world study.. Journal of Clinical Oncology, 2021, 39, e16138-e16138.	0.8	3
34	Landmark analysis of overall survival (OS) by objective response (OR) in previously treated patients (pts) with advanced hepatocellular carcinoma (aHCC): Post hoc analysis of the randomized, phase 3 KEYNOTE-240 study.. Journal of Clinical Oncology, 2021, 39, e16122-e16122.	0.8	0
35	TCOG T5217 trial: A phase II randomized study of SLOG versus modified FOLFIRINOX as the first-line treatment in locally advanced or metastatic pancreatic ductal adenocarcinoma.. Journal of Clinical Oncology, 2021, 39, 4143-4143.	0.8	6
36	Association of gut microbiota and metabolites with tumor response to immune checkpoint inhibitors in patients with unresectable hepatocellular carcinoma.. Journal of Clinical Oncology, 2021, 39, e16165-e16165.	0.8	2

#	ARTICLE	IF	CITATIONS
37	Insulin-Like Growth Factor 2 mRNA-Binding Protein 1 (IGF2BP1) Is a Prognostic Biomarker and Associated with Chemotherapy Responsiveness in Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6940.	1.8	19
38	The efficacy of anti-EGFR therapy in treating metastatic colorectal cancer differs between the middle/low rectum and the left-sided colon. <i>British Journal of Cancer</i> , 2021, 125, 816-825.	2.9	7
39	Cardia Gastric Cancer Is Associated With Increased PIK3CA Amplifications and HER2 Expression Than Noncardia Gastric Cancer According to Lauren Classification. <i>Frontiers in Oncology</i> , 2021, 11, 632609.	1.3	1
40	Abstract CT154: Isatuximab (Isa) plus atezolizumab (Atezo) in patients (pts) with advanced malignancies: Results from a Phase 1/2 open-label multicenter study. , 2021, , .		1
41	Redefining Tumor Burden in Patients with Intermediate-Stage Hepatocellular Carcinoma: The Seven-Eleven Criteria. <i>Liver Cancer</i> , 2021, 10, 629-640.	4.2	27
42	Preference criteria for regorafenib in treating refractory metastatic colorectal cancer are the small tumor burden, slow growth and poor/scanty spread. <i>Scientific Reports</i> , 2021, 11, 15370.	1.6	2
43	Effect of Transarterial Chemoembolization on ALBI Grade in Intermediate-Stage Hepatocellular Carcinoma: Criteria for Unsuitable Cases Selection. <i>Cancers</i> , 2021, 13, 4325.	1.7	8
44	Evolutionary Learning-Derived Clinical-Radiomic Models for Predicting Early Recurrence of Hepatocellular Carcinoma after Resection. <i>Liver Cancer</i> , 2021, 10, 572-582.	4.2	21
45	Affibody-conjugated 5-fluorouracil prodrug system preferentially targets and inhibits HER2-expressing cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2021, 582, 137-143.	1.0	1
46	Genetic alterations in gastric cancer patients according to sex. <i>Aging</i> , 2021, 13, 376-388.	1.4	9
47	Predictors of long-term recurrence and survival after resection of HBV-related hepatocellular carcinoma: the role of HBsAg. <i>American Journal of Cancer Research</i> , 2021, 11, 3711-3725.	1.4	4
48	Survival outcomes of management in metastatic gastric adenocarcinoma patients. <i>Scientific Reports</i> , 2021, 11, 23142.	1.6	21
49	362 Association of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio with clinical outcomes to tislelizumab monotherapy in patients with previously treated advanced hepatocellular carcinoma. , 2021, 9, A389-A389.		0
50	Comparable benefits of HCV eradication by direct acting antivirals and interferon-based therapy in patients with hepatocellular carcinoma undergoing surgical resection. <i>American Journal of Cancer Research</i> , 2021, 11, 5526-5542.	1.4	0
51	Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 846-854.	3.2	90
52	Aspirin is associated with low recurrent risk in hepatitis B virus-related hepatocellular carcinoma patients after curative resection. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 218-229.	0.8	19
53	Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer. <i>Gastric Cancer</i> , 2020, 23, 143-153.	2.7	45
54	Radiological features and outcomes of combined hepatocellular-cholangiocarcinoma in patients undergoing surgical resection. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 125-133.	0.8	14

#	ARTICLE	IF	CITATIONS
55	Outcomes of enteral metallic stent in patients with pancreatic carcinoma and gastric outlet obstruction: A single center experience. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 238-246.	0.8	7
56	A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data. <i>Gastric Cancer</i> , 2020, 23, 510-519.	2.7	155
57	Comparing Late-line Treatment Sequence of Regorafenib and Reduced-intensity FOLFOXIRI for Refractory Metastatic Colorectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 28-34.	0.6	8
58	Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 193-202.	0.8	1,255
59	The clinicopathological characteristics and prognosis of patients with node-positive gastric cancer after curative surgery. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 751-755.	0.6	4
60	Pre-sarcopenia determines post-progression outcomes in advanced hepatocellular carcinoma after sorafenib failure. <i>Scientific Reports</i> , 2020, 10, 18375.	1.6	14
61	Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma. , 2020, 8, e001072.		45
62	Mucinous gastric adenocarcinoma: A good candidate for immune therapy?. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 624-625.	0.6	1
63	The Clinicopathological Characteristics And Genetic Alterations of Signet-ring Cell Carcinoma in Gastric Cancer. <i>Cancers</i> , 2020, 12, 2318.	1.7	18
64	The unique characteristic in peripheral immune cells in patients with advanced hepatocellular carcinoma. <i>Journal of the Formosan Medical Association</i> , 2020, 120, 1581-1590.	0.8	4
65	Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors. , 2020, 8, e000453.		80
66	The Clinicopathological Features and Genetic Alterations in Epsteinâ€Barr Virus-Associated Gastric Cancer Patients after Curative Surgery. <i>Cancers</i> , 2020, 12, 1517.	1.7	24
67	The Clinicopathological Features and Genetic Mutations in Gastric Cancer Patients According to EMAST and MSI Status. <i>Cancers</i> , 2020, 12, 551.	1.7	9
68	Using salvage Boron Neutron Capture Therapy (BNCT) for recurrent malignant brain tumors in Taiwan. <i>Applied Radiation and Isotopes</i> , 2020, 160, 109105.	0.7	28
69	Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22â€05): a single-arm, phase 1bâ€2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1066-1076.	5.1	130
70	The clinicopathological characteristics and genetic alterations of mucinous carcinoma of the stomach. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 141-147.	0.6	10
71	An Open-Label, Single-Arm, Two-Stage, Multicenter, Phase II Study to Evaluate the Efficacy of TLC388 and Genomic Analysis for Poorly Differentiated Neuroendocrine Carcinomas. <i>Oncologist</i> , 2020, 25, e782-e788.	1.9	7
72	Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 182.	1.7	74

#	ARTICLE	IF	CITATIONS
73	Identification of key genes and pathways associated with topotecan treatment using multiple bioinformatics tools. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 446-453.	0.6	3
74	A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy. <i>Oncologist</i> , 2020, 25, e1280-e1285.	1.9	14
75	<i>PRKDC</i>: new biomarker and drug target for checkpoint blockade immunotherapy. , 2020, 8, e000485.		32
76	Pembrolizumab (pembro) versus standard of care chemotherapy (chemo) in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4523-4523.	0.8	9
77	Effect of pembrolizumab (pembro) on hepatitis B viral (HBV) load and aminotransferase (ALT) levels in patients (pts) with advanced hepatocellular carcinoma (aHCC) in KEYNOTE-224 and KEYNOTE-240.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4587-4587.	0.8	2
78	Real-world experience of pembrolizumab plus lenvatinib in unresectable hepatocellular carcinoma in Taiwan.. <i>Journal of Clinical Oncology</i> , 2020, 38, e16627-e16627.	0.8	4
79	ZW25, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: A phase 1B/2 trial-in-progress.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS3145-TPS3145.	0.8	6
80	A phase III study of nivolumab (Nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Three-year update data.. <i>Journal of Clinical Oncology</i> , 2020, 38, 383-383.	0.8	10
81	Phase III study of pembrolizumab (pembro) versus best supportive care (BSC) for second-line therapy in advanced hepatocellular carcinoma (aHCC): KEYNOTE-240 Asian subgroup.. <i>Journal of Clinical Oncology</i> , 2020, 38, 526-526.	0.8	5
82	The clinicopathological characteristics and genetic alterations between younger and older gastric cancer patients with curative surgery. <i>Aging</i> , 2020, 12, 18137-18150.	1.4	7
83	Association between immune and tumor gene signatures with response or resistance to tislelizumab monotherapy or in combination with chemotherapy in gastroesophageal adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3115-3115.	0.8	0
84	DNA damage and repair gene panel as a biomarker of immune checkpoint inhibitor response.. <i>Journal of Clinical Oncology</i> , 2020, 38, e15052-e15052.	0.8	0
85	Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2019, 8, 480-490.	4.2	57
86	A new ALBIâ€based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma. <i>Liver International</i> , 2019, 39, 1704-1712.	1.9	58
87	Identification of phenothiazine as an ETV1â€targeting agent in gastrointestinal stromal tumors using the Connectivity Map. <i>International Journal of Oncology</i> , 2019, 55, 536-546.	1.4	3
88	A phase 0 study of the pharmacokinetics, biodistribution, and dosimetry of 188Re-liposome in patients with metastatic tumors. <i>EJNMMI Research</i> , 2019, 9, 46.	1.1	17
89	Analysis of the clinical significance of DNA methylation in gastric cancer based on a genome-wide high-resolution array. <i>Clinical Epigenetics</i> , 2019, 11, 154.	1.8	9
90	PD-L1 is a double-edged sword in colorectal cancer: the prognostic value of PD-L1 depends on the cell type expressing PD-L1. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1785-1794.	1.2	20

#	ARTICLE	IF	CITATIONS
91	Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis. <i>Journal of Hepatology</i> , 2019, 71, 543-552.	1.8	180
92	Comparison of the Clinicopathological Characteristics and Genetic Alterations Between Patients with Gastric Cancer with or Without <i>Helicobacter pylori</i> Infection. <i>Oncologist</i> , 2019, 24, e845-e853.	1.9	24
93	Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4004-4004.	0.8	149
94	A phase Ib study of IMU-131 HER2/neu peptide vaccine plus chemotherapy in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4030-4030.	0.8	2
95	Lenvatinib for the treatment of HCC: A single institute experience.. <i>Journal of Clinical Oncology</i> , 2019, 37, e15611-e15611.	0.8	7
96	Evaluation of efficacy of nivolumab by baseline factors from ATTRACTION-2.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8-8.	0.8	3
97	A phase II study of ADI-PEG 20 and FOLFOX6 in patients (pts) with advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS477-TPS477.	0.8	2
98	Combined Microsatellite Instability and Elevated Microsatellite Alterations at Selected Tetranucleotide Repeats (EMAST) Might Be a More Promising Immune Biomarker in Colorectal Cancer. <i>Oncologist</i> , 2019, 24, 1534-1542.	1.9	15
99	Expression profile-driven discovery of AURKA as a treatment target for liposarcoma. <i>International Journal of Oncology</i> , 2019, 55, 938-948.	1.4	9
100	A phase Ib/II open label study of IMU-131 HER2/Neu peptide vaccine plus cisplatin and either 5-fluorouracil or capecitabine chemotherapy in patients with HER2/Neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS176-TPS176.	0.8	1
101	Genomic profiling for unfavorable carcinoma of unknown primary patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, e13140-e13140.	0.8	0
102	A phase Ib study of oraxol in combination with ramucirumab in patients with gastric or esophageal cancers who failed previous chemotherapy.. <i>Journal of Clinical Oncology</i> , 2019, 37, e15518-e15518.	0.8	0
103	An open label, single-arm, two-stage, multicenter, phase II study to evaluate the efficacy and safety of TLC388 as second-line treatment in subjects with poorly differentiated neuroendocrine carcinomas (TCOGT1Z14).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4101-4101.	0.8	1
104	The clinical impact of the novel tumor marker DR-70 in unresectable gastric cancer patients. <i>Journal of the Chinese Medical Association</i> , 2018, 81, 593-598.	0.6	4
105	Toxicities, safeties and clinical response of dacarbazine-based chemotherapy on neuroendocrine tumors in Taiwan population. <i>Journal of the Chinese Medical Association</i> , 2018, 81, 423-428.	0.6	1
106	A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2018, 7, 165-178.	4.2	23
107	Validation of the albumin-bilirubin grade-based integrated model as a predictor for sorafenib-failed hepatocellular carcinoma. <i>Liver International</i> , 2018, 38, 321-330.	1.9	37
108	Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 814-824.	1.4	18

#	ARTICLE	IF	CITATIONS
109	Ramucirumab Safety in East Asian Patients: A Meta-Analysis of Six Global, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trials. <i>Journal of Global Oncology</i> , 2018, 4, 1-12.	0.5	7
110	Role of PLK1 signaling pathway genes in gastrointestinal stromal tumors. <i>Oncology Letters</i> , 2018, 16, 3070-3082.	0.8	2
111	Risk of renal events during tenofovir disoproxil fumarate and entecavir antiviral prophylaxis in HBsAg-positive cancer patients undergoing chemotherapy. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1599-1607.	1.0	9
112	TREETOPP: A phase 2/3 study of varlitinib plus capecitabine versus placebo plus capecitabine as second-line treatment in patients with advanced or metastatic biliary tract cancers (BTCs).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS4143-TPS4143.	0.8	3
113	Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials.. <i>Journal of Clinical Oncology</i> , 2018, 36, 90-90.	0.8	1
114	Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15127-e15127.	0.8	0
115	The telomere-binding protein TRF2 is required for metronomic therapeutic effects of gemcitabine and capecitabine. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2017, 1863, 917-928.	1.8	1
116	Evaluation of prognostic factors and implication of lymph node dissection in intrahepatic cholangiocarcinoma: 10-year experience at a tertiary referral center. <i>Journal of the Chinese Medical Association</i> , 2017, 80, 140-146.	0.6	14
117	Complete Response to the Combination of Pembrolizumab and Sorafenib for Metastatic Hepatocellular Carcinoma: A Case Report. <i>American Journal of Gastroenterology</i> , 2017, 112, 659-660.	0.2	14
118	Metallic Stent Expansion Rate at Day One Predicts Stent Patency in Patients with Gastric Outlet Obstruction. <i>Digestive Diseases and Sciences</i> , 2017, 62, 1286-1294.	1.1	16
119	Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2017, 390, 2461-2471.	6.3	1,749
120	A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 2405-2413.	3.2	48
121	Advances in Laparoscopic and Robotic Gastrectomy for Gastric Cancer. <i>Pathology and Oncology Research</i> , 2017, 23, 13-17.	0.9	17
122	Risk of recurrence in chronic hepatitis B patients developing hepatocellular carcinoma with antiviral secondary prevention failure. <i>PLoS ONE</i> , 2017, 12, e0188552.	1.1	6
123	Comparative study of the 7th and 8th AJCC editions for gastric cancer patients after curative surgery. <i>PLoS ONE</i> , 2017, 12, e0187626.	1.1	18
124	PRKDC: A new candidate for checkpoint blockade immunotherapy?. <i>Journal of Clinical Oncology</i> , 2017, 35, 3022-3022.	0.8	6
125	Using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to predict efficacy of axitinib for treatment of advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2017, 35, e15656-e15656.	0.8	1
126	Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastro-esophageal junction cancer (AGC): A double-blinded, randomized, phase III trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2-2.	0.8	64

#	ARTICLE	IF	CITATIONS
127	Efficacy and safety of ramucirumab (RAM) for metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma across age subgroups in two global phase 3 trials.. Journal of Clinical Oncology, 2017, 35, 3-3.	0.8	4
128	Initial signals of efficacy in cholangiocarcinoma from a phase Ib trial of varlitinib in combination with doublet chemotherapy (cisplatin + 5-fluorouracil or capecitabine).. Journal of Clinical Oncology, 2017, 35, e15671-e15671.	0.8	0
129	Genes involved in angiogenesis and mTOR pathways are frequently mutated in Asian patients with pancreatic neuroendocrine tumors. International Journal of Biological Sciences, 2016, 12, 1523-1532.	2.6	31
130	Clinical significance of circulating plasma DNA in gastric cancer. International Journal of Cancer, 2016, 138, 2974-2983.	2.3	68
131	Expression levels of ROS1/ALK/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer. Scientific Reports, 2016, 6, 25369.	1.6	21
132	Oncogenic circuit constituted by Ser31-HBx and Akt increases risks of chronic hepatitis and hepatocellular carcinoma. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 837-849.	1.8	3
133	Helicobacter pylori-induced chronic inflammation causes telomere shortening of gastric mucosa by promoting PARP-1-mediated non-homologous end joining of DNA. Archives of Biochemistry and Biophysics, 2016, 606, 90-98.	1.4	25
134	Antiplatelet Therapy is Associated with a Better Prognosis for Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma after Liver Resection. Annals of Surgical Oncology, 2016, 23, 874-883.	0.7	51
135	Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma. Hepatology, 2016, 64, 774-784.	3.6	77
136	Subgroup analysis of East Asians in RAINBOW: A phase 3 trial of ramucirumab plus paclitaxel for advanced gastric cancer. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 581-589.	1.4	35
137	Akt phosphorylates myc-associated zinc finger protein (MAZ), releases P-MAZ from the p53 promoter, and activates p53 transcription. Cancer Letters, 2016, 375, 9-19.	3.2	15
138	Phase III randomized study of second line ADI-peg 20 (A) plus best supportive care versus placebo (P) plus best supportive care in patients (pts) with advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2016, 34, 4017-4017.	0.8	18
139	PHOCUS: A phase 3 randomized, open-label study comparing the oncolytic immunotherapy Pexa-Vec followed by sorafenib (SOR) vs SOR in patients with advanced hepatocellular carcinoma (HCC) without prior systemic therapy.. Journal of Clinical Oncology, 2016, 34, TPS4146-TPS4146.	0.8	38
140	Mutations in PI3K/AKT pathway genes and amplifications of <i>PIK3CA</i> are associated with patterns of recurrence in gastric cancers. Oncotarget, 2016, 7, 6201-6220.	0.8	61
141	Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial. Oncotarget, 2015, 6, 18162-18173.	0.8	90
142	Determinants of Survival After Sorafenib Failure in Patients With BCLC-C Hepatocellular Carcinoma in Real-World Practice. Medicine (United States), 2015, 94, e688.	0.4	30
143	The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: Final results of the START trial. International Journal of Cancer, 2015, 136, 1458-1467.	2.3	109
144	High neuroendocrine component is a factor for poor prognosis in gastrointestinal high-grade malignant mixed adenoneuroendocrine neoplasms. Journal of the Chinese Medical Association, 2015, 78, 454-459.	0.6	26

#	ARTICLE	IF	CITATIONS
145	A randomized, open-label phase II study of AZD4547 (AZD) versus Paclitaxel (P) in previously treated patients with advanced gastric cancer (AGC) with Fibroblast Growth Factor Receptor 2 (FGFR2) polysomy or gene amplification (amp): SHINE study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4014-4014.	0.8	36
146	RAINBOW: A global, phase 3, double-blind study of ramucirumab (RAM) plus paclitaxel (PTX) versus placebo (PL) plus PTX in the treatment of advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy. An age-group analysis.. <i>Journal of Clinical Oncology</i> , 2015, 33, 11-11.	0.8	5
147	Phase II study of front-line dovitinib (TKI258) versus sorafenib in patients (Pts) with advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 237-237.	0.8	5
148	Efficacy and safety of nintedanib versus sorafenib in Asian patients with advanced hepatocellular carcinoma (HCC): A randomized phase II trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 339-339.	0.8	7
149	A Nation-Wide Cancer Registry-Based Study of Adenosquamous Carcinoma in Taiwan. <i>PLoS ONE</i> , 2015, 10, e0139748.	1.1	9
150	Identification of SPHK1 as a therapeutic target and marker of poor prognosis in cholangiocarcinoma. <i>Oncotarget</i> , 2015, 6, 23594-23608.	0.8	15
151	A phase II study of sequential capecitabine plus oxaliplatin (XELOX) followed by docetaxel plus capecitabine (TX) in patients with unresectable gastric adenocarcinoma: The TCOG T3211 trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4024-4024.	0.8	1
152	Efficacy and safety of nintedanib (N) versus sorafenib (S) in Caucasian and Asian patients with advanced hepatocellular carcinoma (HCC): Pooled analysis of two randomized phase II trials.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4074-4074.	0.8	0
153	Using Modified RECIST and Alpha-Fetoprotein Levels to Assess Treatment Benefit in Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2014, 3, 439-450.	4.2	21
154	A multicenter phase II study of biweekly capecitabine in combination with oxaliplatin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 799-806.	1.1	14
155	Outcome for self-expandable metal stents in patients with malignant gastroduodenal obstruction: A single center experience. <i>Advances in Digestive Medicine</i> , 2014, 1, 1-8.	0.1	4
156	Update on treatment of gastric cancer. <i>Journal of the Chinese Medical Association</i> , 2014, 77, 345-353.	0.6	45
157	Randomized open-label phase 2 study of MM-111 and paclitaxel (PTX) with trastuzumab (TRAS) in patients with HER2-expressing carcinomas of the distal esophagus, gastroesophageal (GE) junction, and stomach who have failed front-line metastatic or locally advanced therapy.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS4148-TPS4148.	0.8	5
158	Impact of ROS1, ALK, and/or MET expression level on the therapeutic efficacy of GEMOX with and without cetuximab in ABTC: A post hoc analysis of a randomized phase II trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 267-267.	0.8	0
159	The risk of second primary malignancy among male breast cancer patients: A population-based study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 1594-1594.	0.8	0
160	Cytokines are associated with postembolization fever and survival in hepatocellular carcinoma patients receiving transcatheter arterial chemoembolization. <i>Hepatology International</i> , 2013, 7, 883-892.	1.9	30
161	A randomized controlled trial of gemcitabine plus cisplatin versus gemcitabine alone in the treatment of metastatic pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 637-642.	1.1	31
162	KRAS mutation status-stratified randomized phase II trial of GEMOX with and without cetuximab in advanced biliary tract cancer (ABTC): The TCOG T1210 trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4018-4018.	0.8	9

#	ARTICLE	IF	CITATIONS
163	Phase IIb randomized trial of Pexa-Vec (pexastimogene devacirepvec; JX-594), a targeted oncolytic vaccinia virus, plus best supportive care (BSC) versus BSC alone in patients with advanced hepatocellular carcinoma who have failed sorafenib treatment (TRAVERSE).. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS4161-TPS4161.	0.8	1
164	Vandetanib in patients with inoperable hepatocellular carcinoma: A phase II, randomized, double-blind, placebo-controlled study. <i>Journal of Hepatology</i> , 2012, 56, 1097-1103.	1.8	91
165	Transarterial chemoembolization can prolong survival for patients with metastatic hepatocellular carcinoma: a propensity score matching analysis. <i>Hepatology International</i> , 2012, 6, 753-762.	1.9	20
166	A phase I/II study of foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2, and VEGFR in advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 4108-4108.	0.8	16
167	Evaluation of transcatheter arterial chemoembolization (TACE) plus sorafenib in Chinese patients with unresectable hepatocellular carcinoma: A subgroup analysis of START trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, e14605-e14605.	0.8	0
168	Concurrence of UGT1A Polymorphism and End-Stage Renal Disease Leads to Severe Toxicities of Irinotecan in a Patient with Metastatic Colon Cancer. <i>Tumori</i> , 2011, 97, 243-247.	0.6	8
169	Phase II study of irinotecan in combination with capecitabine as a first-line chemotherapy in Asian patients with inoperable hepatocellular carcinoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2009, 5, 95-100.	0.7	0
170	Prognostic Significance of Vascular Endothelial Growth Factor, Basic Fibroblast Growth Factor, and Angiogenin in Patients With Resectable Hepatocellular Carcinoma After Surgery. <i>Annals of Surgical Oncology</i> , 2003, 10, 355-362.	0.7	201
171	Life-threatening haemorrhage from a sternal metastatic hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, 684-687.	1.4	8
172	Activation of MAD 2 checkprotein and persistence of cyclin B1/CDC 2 activity associate with paclitaxel-induced apoptosis in human nasopharyngeal carcinoma cells. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2000, 5, 235-241.	2.2	38
173	A novel podophyllotoxin-derived compound GL331 is more potent than its congener VP-16 in killing refractory cancer cells. <i>Pharmaceutical Research</i> , 1999, 16, 997-1002.	1.7	56
174	A multi-centre randomized phase II study of nolatrexed versus doxorubicin in treatment of Chinese patients with advanced hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 1999, 44, 307-311.	1.1	50
175	Phase II study of megestrol acetate in the treatment of hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1997, 12, 277-281.	1.4	25
176	Phase II study of flutamide in the treatment of hepatocellular carcinoma. <i>Cancer</i> , 1996, 77, 635-639.	2.0	54
177	Phase II study of flutamide in the treatment of hepatocellular carcinoma. <i>Cancer</i> , 1996, 77, 635-639.	2.0	5
178	The clinicopathological characteristics and genetic alterations of gastric cancer patients according to the Lauren classification. <i>International Surgery</i> , 0, , .	0.0	1